Eli Lilly (LLY) Fundamentals: Diabetes, Obesity and Oncology

Eli Lilly and Company (NYSE: LLY) has undergone one of the most dramatic revenue transformations in modern pharmaceutical history. In the space of just two years, the Indianapolis-based drugmaker has shifted from a broadly diversified pharma company into one whose growth story is anchored by a pair of blockbuster metabolic medicines — while simultaneously building out a serious oncology franchise that often gets overshadowed by the GLP-1 headlines. For investors trying to understand the eli lilly stock analysis picture in 2026, the challenge is not finding growth; it is understanding how durable that growth is, what the balance sheet looks like after a wave of acquisitions, and whether the valuation multiple already prices in the best-case scenario. This article works through each of those questions using the most recently reported numbers.

Q1 2026 Financial Results: Revenue Surge Continues

Eli Lilly reported first-quarter 2026 results on 30 April 2026, and the headline figures were striking. Worldwide revenue reached $19.8 billion, a 56% increase versus Q1 2025, driven almost entirely by volume growth of 65%, partially offset by a 13% decline in realised prices. Net income on a reported basis came in at $7.4 billion, with diluted earnings per share of $8.26 — a 170% increase year-on-year. On a non-GAAP basis, EPS was $8.55, up 156%.

Gross margin in Q1 2026 was $16.2 billion on a reported basis, representing 81.9% of revenue — a slight 0.6 percentage-point compression versus the same quarter last year, driven by lower realised prices. Research and development expenses rose 28% to $3.5 billion, or 18% of revenue, reflecting continued investment across Lilly's early- and late-stage pipeline. Marketing, selling and administrative expenses increased 19% to $2.9 billion.

Following the strong quarter, Lilly raised its full-year 2026 revenue guidance to a range of $82 billion to $85 billion — a $2 billion increase at both ends — and lifted non-GAAP EPS guidance to $35.50 to $37.00. For context, full-year 2025 revenue was approximately $65.2 billion, itself a 45% increase over 2024. The trajectory of top-line growth has been consistent and steep.

The GLP-1 Engine: Mounjaro and Zepbound

Two products account for the overwhelming majority of Lilly's recent revenue growth. Mounjaro (tirzepatide), approved for type 2 diabetes, generated $8.7 billion in Q1 2026 — a 125% increase versus Q1 2025. US revenue from Mounjaro was $4.2 billion, up 59%, while international revenue surged to $4.4 billion from $1.2 billion a year earlier, driven largely by volume growth following Mounjaro's addition to China's National Reimbursed Drug List (NRDL). The China inclusion also compressed realised prices outside the US, which is a dynamic worth monitoring as international volumes continue to scale.

Zepbound (tirzepatide for obesity) contributed $4.1 billion in Q1 2026 US revenue, up 79% from $2.3 billion in Q1 2025. Zepbound was described by Lilly as the most prescribed weight management medication in 2025. Together, Mounjaro and Zepbound generated roughly $12.8 billion in a single quarter — representing approximately 65% of total Q1 2026 revenue. For full-year 2025, Mounjaro generated approximately $23 billion and Zepbound approximately $13.5 billion.

The competitive landscape in GLP-1 medicines is relevant context. Novo Nordisk (NVO) competes directly with its semaglutide-based products Ozempic and Wegovy. Lilly's tirzepatide is a dual GIP/GLP-1 receptor agonist, a differentiated mechanism that has shown strong clinical outcomes in head-to-head and independent trials. In Q1 2026, Lilly also received US FDA approval for Foundayo (orforglipron), an oral GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions — a meaningful convenience advantage over existing injectable and oral GLP-1 options. Foundayo is now commercially available in the US, adding a third pillar to Lilly's metabolic medicine portfolio.

Eli Lilly Fundamentals: The Oncology Franchise

While the metabolic medicines dominate the revenue picture, Lilly's oncology portfolio is a meaningful and growing contributor that deserves separate attention in any thorough lly stock analysis.

• Verzenio (abemaciclib) — a CDK4/6 inhibitor approved for HR+, HER2-negative breast cancer in both adjuvant and advanced settings. Verzenio generated approximately $5.5 billion in full-year 2025 revenue and has been one of Lilly's most consistent growth drivers over the past three years. Notably, Lilly removed Verzenio from its Key Products definition effective Q1 2026, reflecting its transition to a more mature product phase rather than any deterioration in performance.
• Jaypirca (pirtobrutinib) — a non-covalent BTK inhibitor for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). Jaypirca generated $165 million in Q1 2026, up 79% year-on-year. In Q1 2026, Phase 3 data showed Jaypirca significantly extended progression-free survival when added to a venetoclax time-limited regimen in previously treated CLL/SLL patients — its fourth Phase 3 win in this indication.
• Kisunla (donanemab) — Lilly's Alzheimer's disease therapy, which sits at the intersection of neuroscience and precision medicine. Kisunla generated $124 million in Q1 2026, up from just $22 million in Q1 2025, as commercial uptake builds.
• Retevmo (selpercatinib) — a RET inhibitor that received full FDA traditional approval in July 2026 for locally advanced or metastatic solid tumours with a RET gene fusion. Earlier in 2026, Phase 3 data from the LIBRETTO-432 trial showed an 83% reduction in the risk of cancer recurrence when Retevmo was used as adjuvant therapy in early-stage RET fusion-positive lung cancer — a potentially significant label expansion.

Lilly also disclosed in Q1 2026 that its oncology candidate olomorasib received FDA Breakthrough Therapy designation for previously treated KRAS G12C-mutant advanced pancreatic cancer, one of the hardest-to-treat tumour types. Collectively, the oncology pipeline adds a dimension to the eli lilly fundamentals story that is distinct from the GLP-1 narrative and could become a more prominent revenue contributor over the next three to five years.

Dividend and Capital Allocation

The eli lilly dividend is modest relative to the share price but has been growing consistently. Lilly declared a Q3 2026 cash dividend of $1.73 per share, payable 10 September 2026. The Q1 2026 press release confirmed dividends paid per share of $1.73 in the quarter, up 15% from $1.50 in Q1 2025. At current earnings levels, the payout ratio is approximately 22% of after-tax profit — a conservative level that leaves substantial room for reinvestment and dividend growth.

Capital allocation in 2026 has been heavily weighted towards business development. During Q1 2026 alone, Lilly announced agreements to acquire four companies: Orna Therapeutics (cell therapies), Centessa Pharmaceuticals (sleep-wake disorders), Kelonia Therapeutics (in vivo CAR-T cell therapies) and Ajax Therapeutics (myelofibrosis and polycythemia vera). These acquisitions reflect a deliberate strategy to extend Lilly's pipeline beyond its current commercial portfolio, though they also add to the acquired in-process R&D (IPR&D) charges that periodically weigh on reported earnings. In Q1 2026, IPR&D charges were $584 million, down sharply from $1.6 billion in Q1 2025.

On the balance sheet, Lilly's net long-term debt for the twelve months ending 31 March 2026 was approximately $29.7 billion, a decline of roughly 12% year-on-year. The company's strong and growing operating cash flow provides meaningful capacity to service this debt while continuing to invest in R&D and acquisitions.

LLY Valuation: What the Multiples Show

Understanding the lly valuation requires separating what the numbers measure from what they imply about the future. As of early August 2026, Lilly's trailing twelve-month price-to-earnings (P/E) ratio is approximately 39–40x, depending on the data source — a level that sits near its ten-year median and is modestly below the peer average for large-cap pharmaceutical companies with comparable growth profiles. GSK offers a useful contrast inside that peer group: a large-cap pharmaceutical business whose investment case rests on vaccines, pipeline replenishment and dividend cover rather than on a single fast-growing metabolic franchise, and our GSK stock analysis works through those fundamentals.

The forward P/E, based on Lilly's own updated 2026 non-GAAP EPS guidance midpoint of approximately $36.25, implies a forward multiple in the low-to-mid 30s range at current share prices around $1,150. A PEG ratio (price-to-earnings relative to growth) of approximately 1.6x on a five-year forward basis suggests the market is pricing in continued strong earnings growth but is not assigning an extreme premium relative to that growth rate.

What the multiple reflects is a market that is weighing several factors simultaneously: the extraordinary near-term revenue momentum from Mounjaro and Zepbound; the potential for Foundayo and retatrutide (a triple agonist currently in Phase 3 for obesity and type 2 diabetes) to extend the GLP-1 franchise; the oncology pipeline's long-term optionality; and the risks discussed below. A P/E ratio is simply a ratio — it tells an investor what price the market is currently paying per dollar of earnings, not whether that price is the right one.

Key Risks to Monitor

No eli lilly stock analysis is complete without a clear-eyed look at the risks that could alter the financial trajectory.

• Pricing pressure: Lower realised prices were already a 13% headwind to Q1 2026 revenue growth. Drug price negotiation provisions, ongoing rebate dynamics, and international reference pricing — particularly in China — could continue to compress net selling prices even as volumes grow.
• Concentration risk: Mounjaro and Zepbound together represent roughly 65% of quarterly revenue. Any safety signal, manufacturing disruption, or competitive development affecting tirzepatide would have an outsized impact on the company's financials. AbbVie (ABBV) is the nearest recent precedent for how a large-cap drugmaker manages that kind of single-franchise dependency once exclusivity eventually turns.
• Manufacturing capacity: Lilly has been investing heavily in manufacturing expansion to meet demand for its GLP-1 medicines. Execution risk around capacity ramp-up remains a factor, particularly as Foundayo adds a third product requiring scale.
• Pipeline execution: The company's elevated R&D spend and acquisition activity reflect a bet on future pipeline success. Clinical trial failures or regulatory setbacks — particularly in oncology or the next generation of metabolic medicines — could affect long-term growth expectations.
• Competition: Novo Nordisk (NVO) remains a formidable competitor in GLP-1 medicines, and several other companies are advancing oral and injectable GLP-1 candidates. The competitive dynamics of this market will evolve materially over the next three to five years.
• Tariff and trade uncertainty: Lilly's own forward-looking disclosures flag global macroeconomic conditions, trade disputes and tariff-related costs as factors that could affect results — a risk that is particularly relevant for a company with significant and growing international revenue.

What to Watch Next

The most important near-term data points for anyone tracking eli lilly fundamentals are the Q2 2026 results, which will show whether the 56% revenue growth rate is sustainable or beginning to moderate as year-on-year comparisons become more demanding. Investors will also be watching the commercial uptake of Foundayo, Phase 3 readouts for retatrutide in obesity, and any further regulatory progress for Retevmo and Jaypirca in expanded indications.

Lilly has also announced a planned Investment Community Meeting for 7 December 2026, which is typically an occasion for the company to provide longer-term financial targets and pipeline updates — a potential catalyst for reassessing the growth outlook in either direction.

The picture that emerges from the data is of a company generating exceptional near-term financial results, investing aggressively in its future, and carrying a valuation that reflects high expectations. The three pillars of diabetes, obesity and oncology each have distinct growth drivers and risk profiles. How those pillars perform — individually and together — will determine whether the current financial trajectory continues or begins to moderate. The numbers provide the evidence; the interpretation is for each investor to make.